Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.9%

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shot up 5.9% on Wednesday . The company traded as high as $124.37 and last traded at $124.01. 550,813 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 972,684 shares. The stock had previously closed at $117.12.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SRPT. UBS Group increased their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Barclays increased their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Royal Bank of Canada increased their price target on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Evercore ISI increased their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. Finally, BMO Capital Markets started coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price on the stock. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Price Performance

The company has a 50 day moving average of $126.18 and a 200 day moving average of $110.21. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -20.30 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.50. The business had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.24) EPS. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 in the last ninety days. Insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Vanguard Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after purchasing an additional 41,465 shares during the last quarter. Picton Mahoney Asset Management purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter worth $2,576,000. WCM Investment Management LLC purchased a new position in Sarepta Therapeutics in the fourth quarter valued at about $600,000. Capula Management Ltd purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $1,409,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Sarepta Therapeutics by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company’s stock worth $1,044,000 after acquiring an additional 8,427 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.